The Motley Fool

CSL’s healthy result

Australia’s largest pharmaceutical company, CSL Limited (ASX: CSL) with a market cap of more than $29 billion, has reported a 24% rise in first-half profits as demand for its blood products soars. Net profit came in at US$627 million, while earnings per share jumped 30% to SU124.7 cents, thanks to the effect of the company’s ongoing share buyback.

Showing that the company is also increasing its margins, and becoming more efficient, sales only rose 7% to US2.5 billion. CSL increased the interim dividend to 50 cents per share, unfranked.

Looking at specific product performance, immunoglobulin sales grew 10% to US912 million, while haemophilia product sales rose to US$542 million. Other human health sales climbed by 19% to US$518 million on the back of increased demand for plasma therapies and influenza sales.

Looking forward, the company expects to report profit growth of around 20% for the full 2013 financial year, barring any unforeseen variables. Earnings per share growth will exceed profit growth again, as the company is still only 21% of the way through a $900 million share buyback.

The company continues to invest in research and development, and has a number of studies underway, which if successful should continue to support high levels of growth.

Foolish takeaway

Australian pharmaceutical and healthcare companies continue to impress globally, including CSL, Cochlear Limited (ASX: COH), Acrux Limited (ASX: ACR) and Mesoblast (ASX: MSB). That shows the strength of our biotechnology industry, although not every company is guaranteed success.

Oil, copper, and gold continue to be in high-demand — and their popularity doesn’t look to be slowing. We’ve uncovered three companies poised to benefit from the rising prices of these commodities. Get our brand-new report — “3 High-Risk/High-Reward Resources Stocks” — FREE!

More reading

The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead.  This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. Motley Fool writer/analyst Mike King owns shares in CSL and Cochlear.

NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%...

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.